Skip to Content

Antibodies, Volume 2, Issue 3

2013 September - 6 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (6)

  • Review
  • Open Access
24 Citations
9,892 Views
18 Pages

17 September 2013

Major histocompatibility complex (MHC) class I molecules are key in the immune response against malignant cells by shaping the T-cell repertoire and presenting peptides from endogenous antigens to CD8+ cytotoxic T cells. Because of their unique speci...

(This article belongs to the Special Issue Recombinant Immunotoxins)
  • Article
  • Open Access
4 Citations
7,509 Views
16 Pages

Development of an Antibody for Detection of Rhamnolipids Characterized as a Major Bacterial Virulence Factor

  • Dimitrios C. Giagkas,
  • Theodora Choli-Papadopoulou and
  • Anastasia A. Pantazaki

28 August 2013

Rhamnolipids (RLs), the glycolipidic biosurfactants found initially as exoproducts of the opportunistic pathogen Pseudomonas aeruginosa, are characterized as virulence factors contributing to its pathogenesis infections. However, RLs are also produce...

  • Review
  • Open Access
136 Citations
37,081 Views
49 Pages

Developments and Challenges for mAb-Based Therapeutics

  • Sumit Goswami,
  • Wei Wang,
  • Tsutomu Arakawa and
  • Satoshi Ohtake

16 August 2013

The continuous increase in the number of approved monoclonal antibody (mAb)-based therapy suggests that mAbs, and their derivatives, will continue to be the focus of the biotherapeutics industry for years to come. Although vast improvements in our ca...

(This article belongs to the Special Issue Monoclonal Antibody Preparation against Natural Product and Its Application)
  • Review
  • Open Access
55 Citations
21,260 Views
26 Pages

Molecular Engineering of Therapeutic Cytokines

  • Rodrigo Vazquez-Lombardi,
  • Brendan Roome and
  • Daniel Christ

3 July 2013

Over the past three decades, a large body of work has been directed at the development of therapeutic cytokines. Despite their central role in immune modulation, only a handful of cytokine therapeutics has achieved regulatory approval. One of the maj...

  • Review
  • Open Access
1 Citations
9,141 Views
11 Pages

In Vivo Secretion of Bispecific Antibodies Recruiting Lymphocytic Effector Cells

  • Marta Compte,
  • Natalia Nuñez-Prado,
  • Laura Sanz and
  • Luis Alvarez-Vallina

27 June 2013

Engineered Fc-lacking bispecific antibodies have shown an exceptionally high potency for recruiting lymphocyte effector cells and enhancing antitumor activity, which is under evaluation in several clinical trials. However, current treatment regimens...

(This article belongs to the Special Issue Bispecific Antibodies for Dual Targeting Strategies)
  • Review
  • Open Access
99 Citations
42,000 Views
23 Pages

Antibody Glycosylation and Inflammation

  • Kai-Ting C. Shade and
  • Robert M. Anthony

25 June 2013

IgG antibodies are the basis of some of the most effective therapeutics developed over the last 20 years. These antibodies are highly specific, have long serum-half lives, and can be produced relatively routinely, making them ideal drugs for immunoth...

(This article belongs to the Special Issue Modes of Antibody Action for Cancer Therapy)
XFacebookLinkedIn
Antibodies - ISSN 2073-4468